Pluristem (NSDQ:PSTI) announced a new Phase I clinical trial to treat chronic tendonitis with the company’s PLX-PAD stem cell therapy.
Cell therapy has traditionally been used in cancer and cardiac treatments, but Pluristem is now applying the technology to sports-related injuries, where it has seen an increased interest among athletes and orthopedic surgeons.
Physicians injected the first-ever patient with millions of stem cells derived from human embryos in a clinical trial aimed at proving the treatment is safe for people with spinal cord injuries.
The trial, sponsored by Geron Corp. (NSDQ:GERN), calls for patients to receive the injection within 14 days of the injury. Geron said the main objective of the study is to assess how well patients tolerate the treatment. Later phases of the trial will examine whether the treatment is effective, according to a press release.
MassDevice Network
@MassDevice
LinkedIn
YouTube